Premium
Effect of gemtuzumab ozogamicin on acute myeloid leukaemia blast cells in vitro , as a single agent and combined with other cytotoxic agents
Author(s) -
Morris K. L.,
Adams J. A.,
Liu Yin J. A.
Publication year - 2006
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.06326.x
Subject(s) - gemtuzumab ozogamicin , cytarabine , etoposide , cd33 , calicheamicin , pharmacology , apoptosis , in vitro , myeloid , cytotoxic t cell , immunology , myeloid leukemia , cancer research , medicine , chemistry , chemotherapy , biology , stem cell , biochemistry , cd34 , microbiology and biotechnology
Summary The effect of gemtuzumab ozogamicin (GO) alone, or combined with low‐dose cytarabine or etoposide, on the proliferation of acute myeloid leukaemia blast cells in vitro was investigated. GO alone induced a dose‐dependent inhibition of proliferation although an increase in apoptosis was only seen in a minority of patients. A correlation was found between PgP function and GO sensitivity but not between CD33 or PgP expression and GO. Combinations of GO with varying concentrations of cytarabine or etoposide were additive in inhibiting proliferation, reducing cell viability and increasing apoptosis.